WO2002032373A3 - Estrogen receptor modulators - Google Patents
Estrogen receptor modulators Download PDFInfo
- Publication number
- WO2002032373A3 WO2002032373A3 PCT/US2001/032035 US0132035W WO0232373A3 WO 2002032373 A3 WO2002032373 A3 WO 2002032373A3 US 0132035 W US0132035 W US 0132035W WO 0232373 A3 WO0232373 A3 WO 0232373A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- estrogen
- receptor modulators
- compounds
- estrogen receptor
- functioning
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002424726A CA2424726A1 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
AU2002221269A AU2002221269A1 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
JP2002535612A JP2004511501A (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulator |
EP01987651A EP1328522A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
US10/399,246 US20040044226A1 (en) | 2001-10-15 | 2001-10-15 | Estrogen receptor modulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24158400P | 2000-10-19 | 2000-10-19 | |
US24164000P | 2000-10-19 | 2000-10-19 | |
US60/241,640 | 2000-10-19 | ||
US60/241,584 | 2000-10-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002032373A2 WO2002032373A2 (en) | 2002-04-25 |
WO2002032373A3 true WO2002032373A3 (en) | 2002-07-04 |
Family
ID=26934418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/032035 WO2002032373A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1328522A2 (en) |
JP (1) | JP2004511501A (en) |
AU (1) | AU2002221269A1 (en) |
CA (1) | CA2424726A1 (en) |
WO (1) | WO2002032373A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750213B2 (en) * | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
DE60334202D1 (en) | 2002-04-24 | 2010-10-28 | Merck Sharp & Dohme | MODULATORS OF THE ESTROGEN RECEPTOR |
EP1944301A4 (en) * | 2005-10-27 | 2012-01-04 | Msd Kk | Novel benzoxathiin derivative |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
WO2008091555A2 (en) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
DK2580210T5 (en) | 2010-06-10 | 2017-06-19 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
JP6112625B2 (en) | 2011-12-14 | 2017-04-12 | セラゴン ファーマシューティカルズ,インク. | Fluorinated estrogen receptor modulators and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919814A (en) * | 1997-04-25 | 1999-07-06 | Adir Et Compagnie | Heterocyclic compounds |
US6013607A (en) * | 1996-02-24 | 2000-01-11 | Basf Aktiengesellschaft | 2-hetaroylcyclohexane-1,3-diones |
-
2001
- 2001-10-15 JP JP2002535612A patent/JP2004511501A/en not_active Withdrawn
- 2001-10-15 EP EP01987651A patent/EP1328522A2/en not_active Withdrawn
- 2001-10-15 CA CA002424726A patent/CA2424726A1/en not_active Abandoned
- 2001-10-15 WO PCT/US2001/032035 patent/WO2002032373A2/en not_active Application Discontinuation
- 2001-10-15 AU AU2002221269A patent/AU2002221269A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013607A (en) * | 1996-02-24 | 2000-01-11 | Basf Aktiengesellschaft | 2-hetaroylcyclohexane-1,3-diones |
US5919814A (en) * | 1997-04-25 | 1999-07-06 | Adir Et Compagnie | Heterocyclic compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1328522A2 (en) | 2003-07-23 |
AU2002221269A1 (en) | 2002-04-29 |
CA2424726A1 (en) | 2002-04-25 |
WO2002032373A2 (en) | 2002-04-25 |
JP2004511501A (en) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1048592A1 (en) | Estrogen receptor modulators | |
EP1501819A4 (en) | Estrogen receptor modulators | |
WO2002091993A3 (en) | Estrogen receptor modulators | |
WO2002041835A3 (en) | Estrogen receptor modulators | |
TW200631933A (en) | Estrogen receptor modulators | |
WO2006062876A3 (en) | Estrogen receptor modulators | |
WO2002032377A3 (en) | Estrogen receptor modulators | |
WO2004073612A3 (en) | Estrogen receptor modulators | |
WO2004091488A3 (en) | Estrogen receptor modulators | |
WO2006081152A3 (en) | Estrogen receptor modulators | |
WO2003016270A3 (en) | Selective estrogen receptor modulators | |
WO2002032373A3 (en) | Estrogen receptor modulators | |
WO2007089291A3 (en) | Estrogen receptor modulators | |
AU2003288644A1 (en) | Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof | |
WO2002058639A3 (en) | Pyranoflavonoid compounds and their use as estrogen receptor modulators | |
WO2005097141A3 (en) | Estrogen receptor modulators | |
WO2002053522A3 (en) | Novel estrogen receptor ligands and methods i | |
WO2004073610A3 (en) | Estrogen receptor modulators | |
WO2001077057A3 (en) | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators | |
WO2004026887A3 (en) | Estrogen receptor modulators | |
WO2008057309A3 (en) | Estrogen receptor modulators | |
AR039282A1 (en) | STROGEN RECEIVERS MODULATORS | |
WO2009059806A3 (en) | Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine | |
DOP2002000384A (en) | MODULATORS OF ESTROGEN RECEPTORS. | |
DOP2005000224A (en) | MODULATORS OF STROGEN RECEIVERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002221269 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2424726 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001987651 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10399246 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002535612 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001987651 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001987651 Country of ref document: EP |